Search the Newsreel

Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com

Investing.com reports on a Form 8K filing by MapLight Therapeutics Inc. for August 13th. The article mentions the company's stock symbol MPLT and its daily performance, showing a 1.47% increase.

MapLight Therapeutics stock jumps on $150M private placement

MapLight Therapeutics Inc (NASDAQ:MPLT) shares increased by 5.2% following the announcement of a $150 million private placement financing. The company plans to use the proceeds to advance ML-007C-MA, supporting its VISTA Phase 2 study in Alzheimer’s disease psychosis and the ZEPHYR-2 registrational Phase 3 …

MapLight Therapeutics 2Q 2026: Net loss $60.2M, EPS $(1.32) — 10-Q Summary

MapLight Therapeutics (MPLT) reported a net loss of $60.2 million and a loss per share of $(1.32) for the second quarter of 2026, remaining pre-revenue. The increased loss compared to Q2 2025 was due to a significant ramp in clinical trial activity and operational …

MapLight Therapeutics (Nasdaq: MPLT) boosts cash with $150M private deal

MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics has reported its financial results for Q2 2026, highlighting positive outcomes from its Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia, which is now advancing to Phase 3. The company is primarily focusing its resources on ML-007C-MA, with ongoing enrollment for the …

Maplight Therapeutics (NASDAQ:MPLT) Trading Up 6.4% - Here's Why

Maplight Therapeutics (NASDAQ:MPLT) saw its stock rise by 6.4% in midday trading on Thursday, despite significantly lower trading volume. The company holds a "Moderate Buy" consensus from analysts with an average price target of $31.17, although it recently reported an earnings per share miss. …

MapLight Therapeutics Announces $150 Million Private Placement Financing

MapLight Therapeutics has announced a $150 million private placement financing, selling common stock and pre-funded warrants to institutional and accredited investors. The proceeds will primarily fund the advancement of ML-007C-MA for Alzheimer's disease psychosis and schizophrenia, including ongoing Phase 2 and planned Phase 3 …

Maplight Therapeutics (MPLT) Earnings Date and Reports 2026

MPLT Downgraded by UBS -- Price Target Lowered to $13.00

UBS has downgraded MapLight Therapeutics (MPLT) to Neutral and significantly reduced its price target from $52.00 to $13.00, reflecting growing concerns about the company's financial health. With a GF Score™ of 14/100 and a net insider selling of $13.8 million, the biotechnology firm faces …

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MapLight Therapeutics, Inc. (MPLT) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against MapLight Therapeutics, Inc. (MPLT) following a significant stock drop. The investigation comes after MapLight's Phase 2 trial for its schizophrenia drug candidate reported mixed results, causing its shares to fall more …

Maplight Therapeutics (NASDAQ:MPLT) Shares Down 6.4% - Time to Sell?

MapLight Therapeutics Inc (MPLT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Bronstein, Gewirtz & Grossman, LLC Encourages MapLight Therapeutics, Inc. (MPLT) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MapLight Therapeutics, Inc. (NASDAQ:MPLT) after the company's shares fell over 50% due to mixed Phase 2 trial results for its schizophrenia drug candidate. The firm encourages investors who purchased MapLight …

Maplight Therapeutics (NASDAQ:MPLT) Insider Sells 22,082 Shares of Stock

Maplight Therapeutics (NASDAQ:MPLT) insider James Woodruff Lillie sold 22,082 shares of the company's stock, valued at approximately $276,908, as part of a pre-arranged trading plan. This transaction reduced his direct ownership by 9.84%. Despite reporting an earnings miss, analysts generally maintain a "Buy" rating …

Form 13D/A MapLight Therapeutics For: 3 August By Investing.com

This article from Investing.com announces the filing of Form 13D/A by MapLight Therapeutics for August 3rd. The content is primarily a placeholder for this regulatory filing, indicating its publication date and the company it pertains to. It does not provide further details about the …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against MapLight Therapeutics, Inc. (MPLT) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against MapLight Therapeutics, Inc. (MPLT) after its shares significantly dropped due to mixed Phase 2 trial results for its schizophrenia drug candidate. The firm encourages investors who purchased MapLight securities to learn …

Maplight Therapeutics (MPLT) insider plans sale of 22,082 shares from vested RSUs

James Lillie, an insider at Maplight Therapeutics, Inc. (MPLT), plans to sell up to 22,082 shares of common stock through Jefferies LLC, with an aggregate market value of $287,507.64. These shares are related to vested Restricted Stock Units (RSUs) from July 18, 2025, and …

MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP is investigating MapLight Therapeutics, Inc. (MPLT) for potential securities law violations after the company's shares dropped over 50% due to mixed Phase 2 trial results for its schizophrenia drug candidate. The investigation focuses on whether MapLight made false or …

Maplight Therapeutics (NASDAQ:MPLT) Rating Lowered to Strong Sell at Wall Street Zen

MapLight shares sink on mixed ph. 2 schizophrenia readout

MapLight Therapeutics' shares plummeted over 60% after revealing mixed results from its phase 2 Zephyr trial for schizophrenia treatment ML-007C-MA. While a twice-daily dose met its primary endpoint by significantly reducing disease severity, a once-daily dose did not achieve statistical significance, although it showed …

Maplight Therapeutics (NASDAQ:MPLT) Shares Down 9.2% - What's Next?

Maplight Therapeutics (NASDAQ:MPLT) saw its shares drop by 9.2% to $13.64 with high trading volume. This decline follows the company reporting a quarterly loss of $1.34 per share, missing analyst estimates. Despite the drop and mixed insider trading activity, the stock maintains an average …

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Buy" from Analysts

Maplight Therapeutics, Inc. (NASDAQ:MPLT) has received an average "Buy" recommendation from seventeen research firms, with most analysts issuing buy or strong-buy ratings, despite some recent downward adjustments to price targets. The company's shares opened at $15.02, with a market capitalization of $640.12 million, and …

MapLight CEO on what investors missed in the biotech’s schizophrenia data

MapLight Therapeutics CEO Christopher Kroeger expressed surprise at the market's negative reaction to their schizophrenia drug data, which led to a two-thirds drop in market value despite positive results. He argues that investors are overly focused on a direct comparison of PANSS scores with …

ADAR1 Capital Management LLC Purchases New Position in Maplight Therapeutics, Inc. $MPLT

ADAR1 Capital Management LLC has acquired a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT), purchasing 374,909 shares valued at approximately $7.6 million. This move comes as Maplight Therapeutics faces mixed trial results for its ML-007C-MA drug, with the twice-daily dose showing promise but the …

Maplight Therapeutics (NASDAQ:MPLT) Shares Up 18.2% Following Insider Buying Activity

Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $148,702.40 in Stock

Maplight Therapeutics Director Troy Cox purchased 15,620 shares of the company's stock for $148,702.40 on July 28, 2026, increasing his ownership significantly. This insider acquisition comes as Maplight shares rose 24.3%, despite recent negative news regarding a trial setback and a quarterly loss. The …

MapLight Therapeutics recovers a portion of Monday's 73% rout (MPLT:NASDAQ)

MapLight Therapeutics (MPLT) saw its shares rise 23% on Wednesday, partially recovering from a 73% drop the previous day. The initial collapse was due to mixed Phase 2 results for its schizophrenia drug candidate. The company focuses on central nervous system disorders.

Maplight Therapeutics (NASDAQ:MPLT) Sees Unusually-High Trading Volume - Time to Buy?

Maplight Therapeutics (NASDAQ:MPLT) experienced an unusually high trading volume, with shares surging by 982% following positive Phase 2 ZEPHYR trial results for its schizophrenia treatment ML-007C-MA. Despite a consensus "Buy" rating and a target price of $34.42 from analysts, the company recently missed quarterly …

HC Wainwright Issues Pessimistic Forecast for Maplight Therapeutics (NASDAQ:MPLT) Stock Price

HC Wainwright has lowered its price target for Maplight Therapeutics (NASDAQ:MPLT) to $26 from $45, while retaining a "buy" rating, indicating a potential 162.63% upside despite the stock opening down 72.9% at $9.90. The company recently reported a quarterly EPS loss of $1.34, missing …

Morgan Stanley Downgrades MapLight Therapeutics to Equalweight From Overweight, $34 PT

Morgan Stanley has downgraded MapLight Therapeutics (MPLT) from Overweight to Equalweight, setting a price target of $34. This decision comes after recent news regarding the company, including a significant drop in share price following the failure of its schizophrenia drug in a once-daily test, …

Morgan Stanley Reaffirms "Equal Weight" Rating for Maplight Therapeutics (NASDAQ:MPLT)

Does MapLight Therapeutics’ (MPLT) Dual Symptom And Cognitive Data Hint At A Differentiated Schizophrenia Strategy?

Top Midday Decliners

MapLight Therapeutics' (MPLT) shares tumbled 68% even after the company said its phase 2 trial of ML PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade …